RSV Vaccine in Pregnancy Reduces Baby Hospitalizations by Up to 85%

April 20, 2026 Dr. Michael Lee – Health Editor Health

Respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infection in infants worldwide, with nearly all children infected by age two and a significant proportion requiring hospitalization for bronchiolitis or pneumonia. Recent data from a large-scale maternal immunization trial demonstrates that administering an RSV prefusion F protein-based vaccine during pregnancy substantially reduces the risk of severe RSV disease in newborns, marking a pivotal advancement in passive immunization strategies.

Key Clinical Takeaways:

  • A single dose of RSVpreF vaccine given to pregnant individuals between 24 and 36 weeks gestation reduced infant hospitalization for RSV-associated lower respiratory tract infection by up to 85% within the first 90 days of life.
  • The vaccine’s efficacy stems from transplacental transfer of neutralizing antibodies, providing critical protection during the infant’s most vulnerable window before active immunization becomes feasible.
  • Regulatory agencies including the FDA and EMA have approved maternal RSV vaccination based on robust Phase III trial data showing a favorable safety profile and significant reduction in medically attended RSV illness.

The landmark findings originate from the MATISSE trial (Maternal Immunization Study for Safety and Efficacy), a randomized, double-blind, placebo-controlled Phase III study involving over 7,300 pregnant participants across 18 countries. Published in The New England Journal of Medicine in 2022, the trial demonstrated that infants born to mothers receiving the RSVpreF vaccine had an 81.8% lower risk of severe RSV-associated lower respiratory tract infection requiring medical attention through 90 days post-birth and an 85.7% reduction in hospitalization risk. These results were reinforced by real-world effectiveness data from the 2023–2024 RSV season in the United States, where maternal vaccination correlated with a 78% decrease in infant RSV hospitalizations compared to prior seasons.

Biologically, the vaccine targets the prefusion conformation of the RSV fusion (F) glycoprotein—a highly conserved antigenic site critical for viral entry into host cells. By eliciting high titers of neutralizing IgG antibodies in pregnant individuals, the vaccine facilitates robust transplacental antibody transfer, achieving fetal cord blood concentrations that often exceed maternal levels. This passive immunity bridges the immunological gap until infants can mount their own adaptive responses, typically not until six months of age. Importantly, no vaccine-associated enhanced respiratory disease (VAERD) or significant safety signals were observed in either mothers or infants during extended follow-up.

Funding for the MATISSE trial was provided by Pfizer, which developed the RSVpreF candidate (marketed as Abrysvo®), in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) under a cooperative agreement. The study adhered to FDA guidance on maternal immunization and was monitored by an independent data safety monitoring board. Regulatory approval followed swiftly: the FDA granted approval for Abrysvo® in August 2023 for use in pregnant individuals at 32 through 36 weeks gestation to prevent RSV lower respiratory tract disease in infants from birth through six months of age, with the EMA issuing a similar authorization shortly thereafter.

“Maternal RSV vaccination represents a paradigm shift in how we protect newborns from severe respiratory infections,” states Dr. Flor Munoz, MD, Associate Professor of Pediatrics at Baylor College of Medicine and lead investigator for the U.S. Arm of the MATISSE trial. “By leveraging the natural transfer of maternal antibodies, we’re able to deliver protection precisely when infants are most susceptible—before their immune systems can respond effectively to active vaccination.”

Echoing this sentiment, Dr. Shabir Madhi, PhD, Professor of Vaccinology at the University of the Witwatersrand and co-principal investigator of the trial’s South African site, emphasized the global implications: “In low- and middle-income countries where RSV mortality remains high, this intervention could prevent tens of thousands of infant hospitalizations annually. It’s not just about efficacy—it’s about equity in access to life-saving prevention.”

For expectant parents navigating prenatal care options, consulting with qualified maternal-fetal medicine specialists ensures informed decision-making about vaccinations aligned with current CDC and ACIP recommendations. Individuals seeking guidance on vaccine safety, timing, and eligibility during pregnancy can benefit from discussing concerns with board-certified obstetricians who stay current on emerging immunization protocols. Healthcare systems aiming to implement maternal vaccination programs may benefit from consulting public health administrators experienced in designing perinatal outreach initiatives that improve vaccine uptake in underserved communities.

As maternal RSV vaccination becomes integrated into routine prenatal care, ongoing surveillance will be critical to monitor long-term infant outcomes, assess impact on healthcare utilization, and evaluate potential effects on breastfeeding-related antibody transfer. Future research may explore optimal timing for vaccination in subsequent pregnancies and the potential for combining maternal RSV immunization with other prenatal vaccines, such as those for influenza and pertussis, to streamline preventive care. Continued investment in global access and education will determine how effectively this breakthrough translates into reduced morbidity and mortality across diverse populations.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*

, ,